TriSalus Life Sciences, Inc.
TLSI
$4.76
$0.030.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 28.18% | -32.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.18% | -32.61% | |||
| Cost of Revenue | 22.60% | -30.19% | |||
| Gross Profit | 29.08% | -32.98% | |||
| SG&A Expenses | 28.85% | 5.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.59% | 5.06% | |||
| Operating Income | -16.67% | -157.14% | |||
| Income Before Tax | -695.14% | 115.82% | |||
| Income Tax Expenses | 0.00% | -- | |||
| Earnings from Continuing Operations | -696.95% | 115.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -696.95% | 115.78% | |||
| EBIT | -16.67% | -157.14% | |||
| EBITDA | -16.93% | -163.15% | |||
| EPS Basic | -636.05% | 114.12% | |||
| Normalized Basic EPS | -25.43% | -13.82% | |||
| EPS Diluted | -644.22% | 114.12% | |||
| Normalized Diluted EPS | -25.43% | -13.82% | |||
| Average Basic Shares Outstanding | 11.44% | 11.68% | |||
| Average Diluted Shares Outstanding | 11.44% | 11.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||